Soluble vascular cell adhesion molecule-1 (SVCAM-1) increases tumor resistance to gemcitabine [47]; however, combining gemcitabine with inhibition of the adhesion molecule L1CAM (CD171) reduces VEGF expression and the number of CD31-positive vessels, resulting in a stronger anti-tumor effect [45]. The gene discussed is VEGFA; the disease is neoplasm.